Why Is PHIBRO ANIMAL HEALTH A (PAHC) Stock Moving Today?

Phibro Animal Health (PAHC) stock rose 5.03% to $38.18 in early trading on August 27, 2026, driven by strong earnings results and updated guidance from the company. The stock opened at $36.36 and quickly surged to a session high of $38.22 shortly after the market opened. The move reflects positive investor reaction to record fiscal 2026 sales, a significant increase in adjusted EBITDA, and updated fiscal 2027 sales and earnings projections.

What Happened

Phibro Animal Health reported record fiscal 2026 sales and a sharp rise in adjusted EBITDA, driven by growth in its Animal Health and Mineral Nutrition segments. The company also announced updated guidance for fiscal 2027, projecting net sales of $1.55 billion to $1.6 billion. These figures exceeded analyst expectations, with adjusted EPS guidance of $3.41 to $3.59 and GAAP EPS of $2.98 to $3.22. The Q4 fiscal 2026 earnings call highlighted the integration of its Zoe acquisition and ongoing cost management efforts. The company also announced plans to close its Chicago Heights facility in summer 2027, which will affect approximately 100 employees.

What The Data Shows

The stock opened at $36.36 and climbed steadily, reaching a high of $38.22 within 10 minutes of the market open. The volume so far is 0.0M shares, which is 0.0x the 3-month average. Phibro has a market cap of $1.5 billion and a P/E ratio of 15.0, with trailing 12-month revenue up 17.1%. The stock is currently trading within its 52-week range of $28.25 to $60.08. On August 28, the stock printed eight fresh 52-week highs. Recent insider transactions include a $318,000 buy by director Corcoran E. Thomas on May 29, while former President Donald J. Trump sold between $1,001 and $15,000 of the stock on May 15.

What To Watch

Phibro Animal Health has no upcoming earnings date to note, but coverage of its recent earnings call and strategic updates is expected to expand over the next few days. Investors should monitor the breadth of analyst commentary and any follow-up on the company’s plant closure plans and regulatory developments in Brazil.